Publication: The preclinical activities of PTC596, a novel tubulin-binding agent that down-regulates BMI1, alone and in combination with bortezomib in multiple myeloma (MM)

This research article, published in Blooddetails preclinical anti-tumor activity of PTC596 alone, and in combination with bortezomibin vitro and in vivo 

  • This paper reports on preclinical activity of PTC596 – a novel agent which kills cancer stem cells and reduces BMI1 activity – in MM models
  • Cytotoxic effects of PTC596, alone and in combination with bortezomib, on human MM cell lines were measured and the mechanism of action is detailed
  • Results from tests involving oral administration of PTC596 in immunodeficient mice – alone and in combination with subcutaneous bortezomib – are reported

Nagai Y, Mimura N, Rizq O, et al. Blood. 2019;134 (Supplement 1):4414 

Once registered, you will be provided the DOI for this publication. 

Register now to unlock the content

Register now to access the content on this page

Already registered?
If not, register below

  • This Website is intended only for healthcare professionals (“Website“), is operated by PTC Therapeutics. (together with its affiliates “PTC”). In order to access the restricted content on this Website:

  • PTC will delete immediately the information provided if we cannot confirm you are healthcare professional.
    Otherwise, in case of successful verification, PTC will retain the information provided for a period of two (2) years two (2) years following your registration (i) only for the purposes of providing you access to this Website; and/or (ii) in case you signed up to receive PTC updates.

Providing your personal data and your consent is voluntary, and you have the right to withdraw your consent at any time, without giving any reasons. Please consult our Privacy Statement for more information on the processing of your personal data.
For any enquiry relating to the processing of your personal data or if you want to exercise your privacy related rights or withdraw your consent, you can contact PTC’s Privacy Office at:

You can unsubscribe from updates at any time when receiving an email from PTC.

MED-ALL-DIPG-2100031 | March 2023
Sign in or register to access exclusive content on this site 

Welcome to MEDhub

A website for healthcare professionals, provided by PTC Therapeutics

This educational website provides you with the latest scientific data and expert
insights on the diagnosis and management of a range of rare diseases across the neuromuscular system, central nervous system, and other areas

This content is protected. To view it please enter your email address below:

Register here to access the content on the site
MED-ALL-CORP-2200029 | October 2023


The content you are trying to access is not currently available.

We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.